Innovative nanotechnologies for the delivery of oligonucleotides and siRNA
- PMID: 16952435
- DOI: 10.1016/j.biopha.2006.07.093
Innovative nanotechnologies for the delivery of oligonucleotides and siRNA
Abstract
One way to reach intracellular therapeutic targets in cells consists in the use of short nucleic acids which will bind specifically to on targets thanks to either Watson-Crick base pairing or protein nucleic acids recognition rules. Among these short nucleic acids an important class of therapeutic agents is antisense oligonucleotides and siRNAs. However, the major problem of nucleic acids is their poor stability in biological media. One method, among others, to solve the stability problem is the use of colloïdal carriers such as nanoparticles. Nanoparticles have already been applied with success to in vitro drug delivery to particular types of cells and in vivo in several experimental models. Many membrane and intracellular processes deal with nanosized structure (typically 100 nm) which are processed further through the recognition sites of receptors and enzymes. Thus non-viral nanoparticles are interesting candidates to present biochemical molecules such as nucleic acids and proteins to cells as well as to protect them in vivo during delivery. This review focuses on the recent developments in the design of nanotechnologies to improve the delivery of antisense oligonucleotides and siRNAs.
Similar articles
-
Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA.Eur J Pharm Biopharm. 2009 Mar;71(3):490-504. doi: 10.1016/j.ejpb.2008.09.024. Epub 2008 Nov 1. Eur J Pharm Biopharm. 2009. PMID: 18977435 Review.
-
State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers.Int J Pharm. 2008 Dec 8;364(2):237-48. doi: 10.1016/j.ijpharm.2008.06.011. Epub 2008 Jun 19. Int J Pharm. 2008. PMID: 18619528 Review.
-
Oral delivery of siRNA and antisense oligonucleotides.J Drug Target. 2009 Aug;17(7):491-5. doi: 10.1080/10611860903057674. J Drug Target. 2009. PMID: 19530907
-
Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.Adv Drug Deliv Rev. 2006 Nov 15;58(11):1203-23. doi: 10.1016/j.addr.2006.07.020. Epub 2006 Sep 15. Adv Drug Deliv Rev. 2006. PMID: 17097190 Review.
-
Can we better understand the intracellular behavior of DNA nanoparticles by fluorescence correlation spectroscopy?J Control Release. 2007 Aug 16;121(1-2):49-63. doi: 10.1016/j.jconrel.2007.04.008. Epub 2007 Apr 19. J Control Release. 2007. PMID: 17509716
Cited by
-
Alternative for anti-TNF antibodies for arthritis treatment.Mol Ther. 2011 Oct;19(10):1887-95. doi: 10.1038/mt.2011.156. Epub 2011 Aug 2. Mol Ther. 2011. PMID: 21811249 Free PMC article.
-
Noble metal nanoparticles applications in cancer.J Drug Deliv. 2012;2012:751075. doi: 10.1155/2012/751075. Epub 2011 Oct 5. J Drug Deliv. 2012. PMID: 22007307 Free PMC article.
-
Cationic shell-cross-linked knedel-like (cSCK) nanoparticles for highly efficient PNA delivery.Mol Pharm. 2009 Mar-Apr;6(2):615-26. doi: 10.1021/mp800199w. Mol Pharm. 2009. PMID: 19231840 Free PMC article.
-
Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.Nucleic Acids Res. 2012 Jul;40(13):6319-37. doi: 10.1093/nar/gks294. Epub 2012 Mar 30. Nucleic Acids Res. 2012. PMID: 22467215 Free PMC article.
-
Small RNA- and DNA-based gene therapy for the treatment of liver cirrhosis, where we are?World J Gastroenterol. 2014 Oct 28;20(40):14696-705. doi: 10.3748/wjg.v20.i40.14696. World J Gastroenterol. 2014. PMID: 25356032 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources